AUS
NZ
UK
CA
USA
IND
Healthcare
Novo Nordisk (NYSE:NVO) Share Slump Creates Tension Before Key Updates Arrive
February 26, 2026 12:55 PM PST| By Anmol KhazanchiNovo Nordisk operates in the global healthcare and pharmaceutical sector, with a core focus on diabetes care and weight management therapies that are distributed across North America and other regions.
Agilent (NYSE:A) S&P 500 Index Slides on Target Cut
February 26, 2026 12:36 PM PST| By Anmol KhazanchiAgilent Technologies declines within the s&p 500 following a target revision and earnings miss, with fiscal guidance and operational initiatives remaining central.
-Copy_02_19_2025_19_14_16_993300.jpg)
How Neogen (NASDAQ:NEOG) Is Impacting the Nasdaq 100 Index This Week?
February 26, 2026 12:00 AM PST| By Anmol KhazanchiNeogen (NASDAQ:NEOG) continues strong performance in the diagnostics and food safety sectors, surpassing benchmarks. As part of the Nasdaq 100 Index, it plays a significant role in shaping market trends in healthcare.
How MannKind (NASDAQ:MNKD) Contributes To Nasdaq Futures In Biopharma Market?
February 26, 2026 12:00 AM PST| By Anmol KhazanchiMannKind (NASDAQ:MNKD) faces a dip in stock value, but as part of Nasdaq Futures, its performance continues to impact market sentiment. With its innovative drug-delivery platform, MannKind remains a key player in biopharma.
Merck (NYSE:MRK) In The S&P 500 Index Leading Biopharma With Key Products
February 26, 2026 12:00 AM PST| By Anmol KhazanchiMerck & Co. (NYSE:MRK) is a global leader in biopharmaceuticals, with strong financial performance and a significant role in the S&P 500 Index. Its focus on oncology, vaccines, and R&D positions it for continued market leadership.
Merck Company Inc (NYSE:MRK) Healthcare Strength In Russell 1000 index
February 25, 2026 01:14 PM PST| By Anmol KhazanchiMerck & Co., Inc. operates within the global biopharmaceutical sector, focusing on the discovery, development, manufacturing, and distribution of prescription medicines, vaccines, biologic therapies, and animal health products.
Universal Health Services (NYSE:UHS) Valuation After Pressure Now Matters To S&P 500
February 25, 2026 11:12 AM PST| By Anmol KhazanchiUniversal Health Services sits in the healthcare services sector, with operations spanning acute care hospitals and behavioural health facilities across multiple regions.
Axsome (NASDAQ:AXSM) Reaches New Heights In The Nasdaq Index Fund
February 25, 2026 12:00 AM PST| By Anmol KhazanchiAxsome Therapeutics (NASDAQ:AXSM) has gained institutional support and market attention, with strong growth in its CNS-focused pipeline. As part of the Nasdaq Index Fund, it remains a key player in biopharma.
Arvinas (NASDAQ:ARVN) Moves Higher In Nasdaq Futures With Promising Pipeline
February 25, 2026 12:00 AM PST| By Anmol KhazanchiArvinas (NASDAQ:ARVN), a leader in targeted protein degradation therapies, progresses in clinical trials and attracts market interest. As part of Nasdaq Futures, it remains a key player in biopharmaceutical innovation.
Merck (NYSE:MRK) Hits Annual High in Russell 1000
February 23, 2026 02:56 PM PST| By Anmol KhazanchiMerck reports strong quarterly results, announces oncology unit restructuring, and advances pipeline developments while trading near highs within the Russell 1000 index.
Eli Lilly (NYSE:LLY) Development Updates Drive Buzz As S&P 500 Futures
February 23, 2026 12:33 PM PST| By Anmol KhazanchiEli Lilly operates in the healthcare sector as a global pharmaceutical manufacturer with commercial medicines and a broad research portfolio across immunology, oncology, and metabolic health.
Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Share Momentum
February 23, 2026 10:51 AM PST| By Anmol KhazanchiTeva Pharmaceutical Industries operates in the pharmaceuticals sector, with a business mix spanning generic medicines, select branded medicines, and complex therapies that require advanced manufacturing.
NeoGenomics (NASDAQ:NEO) Gains Traction In Nasdaq Index Mid-Cap Healthcare
February 23, 2026 12:00 AM PST| By Anmol KhazanchiNeoGenomics (NASDAQ:NEO) exceeded quarterly expectations, reinforcing valuation discussion as institutional activity and broader Nasdaq index sentiment shape trading dynamics.
Oscar Health (NYSE:OSCR) Slides on NYSE Composite Indices Earnings
February 22, 2026 01:04 PM PST| By Anmol KhazanchiOscar Health developments on the NYSE Composite reflect ownership shifts, mixed research coverage, and earnings updates across the competitive technology driven insurance market.
Select Medical (NYSE:SEM) Facing Market Pressure After Sector Weakness Hits Healthcare
February 20, 2026 11:25 AM PST| By Anmol KhazanchiThe healthcare services sector plays a crucial role in supporting patients recovering from complex illnesses, surgical procedures, and physical injuries. Companies operating in this space often manage specialized hospitals.
Pediatrix (NYSE:MD) Slips on EPS Miss; NYSE Composite Reaction
February 20, 2026 10:08 AM PST| By Anmol KhazanchiPediatrix Medical Group posts quarterly earnings below expectations with stable liquidity and ongoing clinical expansion as part of the NYSE Composite healthcare segment.
Is Xenon Pharmaceuticals (NASDAQ:XENE) Rising In The Nasdaq Index
February 20, 2026 12:00 AM PST| By Team Kalkine MediaXenon Pharmaceuticals Inc. (NASDAQ:XENE) draws attention amid institutional activity, valuation benchmarks, and broader nasdaq index market momentum.
Alvotech (NASDAQ:ALVO) Faces Valuation Reset As Nasdaq Futures Turn
February 20, 2026 12:00 AM PST| By Anmol KhazanchiAlvotech (NASDAQ:ALVO) faces rating adjustment amid broader biotech momentum shaped by Nasdaq Futures and exchange-wide liquidity trends.
Is AtriCure (NASDAQ:ATRC) Facing New Pressure In The Nasdaq Index?
February 20, 2026 12:00 AM PST| By Anmol KhazanchiAtriCure (NASDAQ:ATRC) faces brokerage downgrade while Nasdaq Index activity influences medical device sector valuation and trading tone.
Is Nuvalent (NASDAQ:NUVL) Entering a Key Phase With Nasdaq Index Fund
February 20, 2026 12:00 AM PST| By Anmol KhazanchiNuvalent (NASDAQ:NUVL) draws attention as brokerage consensus and institutional activity align with Nasdaq Index Fund biotechnology momentum.
